About Interius Biotherapeutics
Interius Biotherapeutics is a company based in Philadelphia (United States) founded in 2020 was acquired by Kite Pharma in August 2025.. Interius Biotherapeutics has raised $129.03 million across 4 funding rounds from investors including Pfizer, BrightEdge and Kite Pharma. The company has 25 employees as of December 31, 2021. Interius Biotherapeutics offers products and services including LENTIVECTOR Platform, INT2104, and INT2106. Interius Biotherapeutics operates in a competitive market with competitors including Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others.
- Headquarter Philadelphia, United States
- Employees 25 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Interius Biotherapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$129.03 M (USD)
in 4 rounds
-
Latest Funding Round
$51.43 M (USD), Series A
May 21, 2024
-
Investors
Pfizer
& 16 more
-
Employee Count
25
as on Dec 31, 2021
-
Acquired by
Kite Pharma
(Aug 22, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Interius Biotherapeutics
Interius Biotherapeutics offers a comprehensive portfolio of products and services, including LENTIVECTOR Platform, INT2104, and INT2106. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
System for precise delivery of genetic medicines to treat diseases.
Lentivector-based treatment targeting oncology applications.
Advanced therapeutic for autoimmunity via genetic medicine.
Unlock access to complete
Unlock access to complete
Funding Insights of Interius Biotherapeutics
Interius Biotherapeutics has successfully raised a total of $129.03M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $51.43 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $51.4M
-
First Round
First Round
(01 Mar 2020)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series A - Interius Biotherapeutics | Valuation |
investors |
|
| Oct, 2023 | Amount | Debt – Conventional - Interius Biotherapeutics | Valuation |
investors |
|
| May, 2021 | Amount | Series A - Interius Biotherapeutics | Valuation | Fairmount Funds Management , Cormorant Asset Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Interius Biotherapeutics
Interius Biotherapeutics has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, BrightEdge and Kite Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Interius Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Interius Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Interius Biotherapeutics Comparisons
Competitors of Interius Biotherapeutics
Interius Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Interius Biotherapeutics
Frequently Asked Questions about Interius Biotherapeutics
When was Interius Biotherapeutics founded?
Interius Biotherapeutics was founded in 2020.
Where is Interius Biotherapeutics located?
Interius Biotherapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Is Interius Biotherapeutics a funded company?
Interius Biotherapeutics is a funded company, having raised a total of $129.03M across 4 funding rounds to date. The company's 1st funding round was a Series A of $76M, raised on Mar 01, 2020.
How many employees does Interius Biotherapeutics have?
As of Dec 31, 2021, the latest employee count at Interius Biotherapeutics is 25.
What does Interius Biotherapeutics do?
Interius Biotherapeutics was founded in 2020 in Philadelphia, United States, within the biotherapeutics sector. Gene therapies targeting various diseases are developed through lentiviral pseudotyping to improve efficiency. In-vivo generation of therapeutic cells, such as CAR-T cells for cancers, regulatory T cells for autoimmune conditions, and CD34 hematopoietic stem cells for blood disorders, is focused on by the company. Operations emphasize innovative cell transformation methods.
Who are the top competitors of Interius Biotherapeutics?
Interius Biotherapeutics's top competitors include Moderna, argenx and Forge Biologics.
What products or services does Interius Biotherapeutics offer?
Interius Biotherapeutics offers LENTIVECTOR Platform, INT2104, and INT2106.
Who are Interius Biotherapeutics's investors?
Interius Biotherapeutics has 17 investors. Key investors include Pfizer, BrightEdge, Kite Pharma, Penn Medicine, and RA Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.